Podcast appearances and mentions of Vanita R Aroda

  • 14PODCASTS
  • 42EPISODES
  • 43mAVG DURATION
  • 1EPISODE EVERY OTHER WEEK
  • Oct 21, 2024LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about Vanita R Aroda

Latest podcast episodes about Vanita R Aroda

Fitness mit M.A.R.K. — Dein Nackt Gut Aussehen Podcast übers Abnehmen, Muskelaufbau und Motivation
Solltest Du Vitamin D einnehmen? Das sagt die Wissenschaft (#494)

Fitness mit M.A.R.K. — Dein Nackt Gut Aussehen Podcast übers Abnehmen, Muskelaufbau und Motivation

Play Episode Listen Later Oct 21, 2024 40:03


Was man teilweise über Vitamin D hört, klingt fast zu schön, um wahr zu sein. Andererseits deuten hunderte verschiedener Forschungsarbeiten darauf hin, dass Vitamin D zur Vorbeugung einer Reihe von Krankheiten beitragen kann – darunter Osteoporose, Depression, Autoimmun- und Herz-Kreislauf-Erkrankungen. Ärzte empfehlen es. Gesundheits- und Fitnesspodcaster sprechen darüber. Vielleicht geht Dir sogar Deine Lieblingstante damit auf die Nerven. Bei all dem Hype ist die Frage berechtigt: "Solltest Du Vitamin D einnehmen?" Hier sind die Antworten – und die neuesten Fakten über ein faszinierendes Vitamin, das ein wahrer Verwandlungskünstler ist. ____________ *WERBUNG: KoRoDrogerie.de: 5% Ermäßigung auf alles mit dem Code „FMM“ beim Checkout. ____________ Ressourcen zur Folge: Literatur: Ratgeber Nahrungsergänzung – Mark Maslow (kostenlos auf MarathonFitness) Blut: Die Geheimnisse unseres flüssigen Organs* – Ulrich Strunz (Heyne) Vitamin D* – Uwe Gröber, Michael F. Holick (Wissenschaftl. Verlagsgesellschaft) Blutuntersuchung (Selbsttest): Vitamin D Test* von Medivere Präparate: D-Form 2.000 K2+* von FormMed D-Form 2.000 K2+ vegan* von FormMed ____________

covid-19 women health man food depression medicine cancer institute nutrition patients journal disease treatments effects hype comparison deutschland prevention diabetes bei bone implications committee ideen antworten older essen gesundheit vielleicht hughes khan clinical li outcomes function evaluation obesity edited ky vitamins checkout reihe sonne fakten wang vitamin d progression advances american society american colleges norton immune system metabolism ressourcen krankheiten sagt zhang internal medicine anne marie nerven yin mena magnesium sunlight efficacy international journal nutrients k2 cardiology american journal critical role chronic disease johansson calcium functioning prevalence aufruf circulation new england journal vitamine resta erm kimball solltest du predictors clinical research annals andererseits american federation valerio gesundheits deng clinical nutrition british journal meta analysis preventive medicine european journal wl beckman cashman die wissenschaft jutta palumbo older men reinhold zito circulating vitamin k vorbeugung observational wacker atherosclerosis osteoporose life stages younger men mandal nutritional supplements mineralien michael f anglin mineralstoffe herz kreislauf erkrankungen sun exposure kevin d vitamin d deficiency quaranta respiratory health einnehmen clinical implications clinical studies versorgungslage forschungsarbeiten endocrine society clinical endocrinology cureus us population maria g vieth glycemic control am j clin nutr american osteopathic association vitamin d supplementation markus k postmenopausal women autoimmun earthman developed countries mark maslow xinyi mariana costa vitamin d2 melhus pittas verwandlungsk mental science experimental immunology dierkes medical hypotheses vitamin d status samantha m nutrition examination survey nhanes masterjohn bmc medicine mineral research dietary reference intakes vanita r aroda calcitriol michael f holick joann e manson catharine ross
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Vanita R. Aroda, MD - Transforming T2DM Treatment in Primary Care: Discerning the Glycemic and Extra-Glycemic Effects of GLP-1 RAs

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later Aug 15, 2024 64:40


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YWP865. CME/NCPD/AAPA/IPCE credit will be available until August 6, 2025.Transforming T2DM Treatment in Primary Care: Discerning the Glycemic and Extra-Glycemic Effects of GLP-1 RAs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Vanita R. Aroda, MD - Transforming T2DM Treatment in Primary Care: Discerning the Glycemic and Extra-Glycemic Effects of GLP-1 RAs

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Aug 15, 2024 64:40


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YWP865. CME/NCPD/AAPA/IPCE credit will be available until August 6, 2025.Transforming T2DM Treatment in Primary Care: Discerning the Glycemic and Extra-Glycemic Effects of GLP-1 RAs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Vanita R. Aroda, MD - Transforming T2DM Treatment in Primary Care: Discerning the Glycemic and Extra-Glycemic Effects of GLP-1 RAs

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Aug 15, 2024 64:40


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YWP865. CME/NCPD/AAPA/IPCE credit will be available until August 6, 2025.Transforming T2DM Treatment in Primary Care: Discerning the Glycemic and Extra-Glycemic Effects of GLP-1 RAs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Vanita R. Aroda, MD - Transforming T2DM Treatment in Primary Care: Discerning the Glycemic and Extra-Glycemic Effects of GLP-1 RAs

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Aug 15, 2024 64:40


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YWP865. CME/NCPD/AAPA/IPCE credit will be available until August 6, 2025.Transforming T2DM Treatment in Primary Care: Discerning the Glycemic and Extra-Glycemic Effects of GLP-1 RAs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Vanita R. Aroda, MD - Transforming T2DM Treatment in Primary Care: Discerning the Glycemic and Extra-Glycemic Effects of GLP-1 RAs

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later Aug 15, 2024 64:40


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YWP865. CME/NCPD/AAPA/IPCE credit will be available until August 6, 2025.Transforming T2DM Treatment in Primary Care: Discerning the Glycemic and Extra-Glycemic Effects of GLP-1 RAs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Vanita R. Aroda, MD - Transforming T2DM Treatment in Primary Care: Discerning the Glycemic and Extra-Glycemic Effects of GLP-1 RAs

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Aug 15, 2024 64:40


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YWP865. CME/NCPD/AAPA/IPCE credit will be available until August 6, 2025.Transforming T2DM Treatment in Primary Care: Discerning the Glycemic and Extra-Glycemic Effects of GLP-1 RAs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Vanita R. Aroda, MD - Leveraging Early GLP-1 RA Initiation to Reduce Risks and Improve Long-Term Outcomes in Patients With T2DM

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 28, 2023 58:55


Go online to PeerView.com/WEU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. People with type 2 diabetes mellitus (T2DM) deserve care that is timely and of the appropriate intensity to reduce risks and improve long-term outcomes. To that end, GLP-1 receptor agonists (RAs) must be considered in a new light. Their role has escalated in recent years, including their positioning in treatment, due to their multifaceted mechanisms of action and the collective body of evidence validating their glycemic and extra-glycemic effects. In fact, these agents have consistently demonstrated high glycemic efficacy while reducing cardiovascular and renal risks with a favorable impact on weight and a low risk of hypoglycemia in patients with T2DM. Watch this expert-led activity to learn about GLP-1 RA options and get practical advice for integrating them into personalized care. Upon completion of this activity, participants should be better able to: Differentiate GLP-1 RAs and other glucose-lowering agents with regard to their current placement in treatment guidelines, glycemic and extra-glycemic effects, safety, ease of administration, and dosing frequency; Identify people with T2DM who would benefit from the glycemic and extra-glycemic effects of GLP-1 RAs to reduce cardiometabolic and renal risks, improve long-term health outcomes, and increase treatment adherence; and Incorporate GLP-1 RAs into personalized treatment regimens early to reduce cardiometabolic and renal risks in people with T2DM

PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
Vanita R. Aroda, MD - Leveraging Early GLP-1 RA Initiation to Reduce Risks and Improve Long-Term Outcomes in Patients With T2DM

PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 28, 2023 58:55


Go online to PeerView.com/WEU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. People with type 2 diabetes mellitus (T2DM) deserve care that is timely and of the appropriate intensity to reduce risks and improve long-term outcomes. To that end, GLP-1 receptor agonists (RAs) must be considered in a new light. Their role has escalated in recent years, including their positioning in treatment, due to their multifaceted mechanisms of action and the collective body of evidence validating their glycemic and extra-glycemic effects. In fact, these agents have consistently demonstrated high glycemic efficacy while reducing cardiovascular and renal risks with a favorable impact on weight and a low risk of hypoglycemia in patients with T2DM. Watch this expert-led activity to learn about GLP-1 RA options and get practical advice for integrating them into personalized care. Upon completion of this activity, participants should be better able to: Differentiate GLP-1 RAs and other glucose-lowering agents with regard to their current placement in treatment guidelines, glycemic and extra-glycemic effects, safety, ease of administration, and dosing frequency; Identify people with T2DM who would benefit from the glycemic and extra-glycemic effects of GLP-1 RAs to reduce cardiometabolic and renal risks, improve long-term health outcomes, and increase treatment adherence; and Incorporate GLP-1 RAs into personalized treatment regimens early to reduce cardiometabolic and renal risks in people with T2DM

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Vanita R. Aroda, MD - Leveraging Early GLP-1 RA Initiation to Reduce Risks and Improve Long-Term Outcomes in Patients With T2DM

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 28, 2023 58:51


Go online to PeerView.com/WEU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. People with type 2 diabetes mellitus (T2DM) deserve care that is timely and of the appropriate intensity to reduce risks and improve long-term outcomes. To that end, GLP-1 receptor agonists (RAs) must be considered in a new light. Their role has escalated in recent years, including their positioning in treatment, due to their multifaceted mechanisms of action and the collective body of evidence validating their glycemic and extra-glycemic effects. In fact, these agents have consistently demonstrated high glycemic efficacy while reducing cardiovascular and renal risks with a favorable impact on weight and a low risk of hypoglycemia in patients with T2DM. Watch this expert-led activity to learn about GLP-1 RA options and get practical advice for integrating them into personalized care. Upon completion of this activity, participants should be better able to: Differentiate GLP-1 RAs and other glucose-lowering agents with regard to their current placement in treatment guidelines, glycemic and extra-glycemic effects, safety, ease of administration, and dosing frequency; Identify people with T2DM who would benefit from the glycemic and extra-glycemic effects of GLP-1 RAs to reduce cardiometabolic and renal risks, improve long-term health outcomes, and increase treatment adherence; and Incorporate GLP-1 RAs into personalized treatment regimens early to reduce cardiometabolic and renal risks in people with T2DM

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Vanita R. Aroda, MD - Leveraging Early GLP-1 RA Initiation to Reduce Risks and Improve Long-Term Outcomes in Patients With T2DM

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 28, 2023 58:55


Go online to PeerView.com/WEU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. People with type 2 diabetes mellitus (T2DM) deserve care that is timely and of the appropriate intensity to reduce risks and improve long-term outcomes. To that end, GLP-1 receptor agonists (RAs) must be considered in a new light. Their role has escalated in recent years, including their positioning in treatment, due to their multifaceted mechanisms of action and the collective body of evidence validating their glycemic and extra-glycemic effects. In fact, these agents have consistently demonstrated high glycemic efficacy while reducing cardiovascular and renal risks with a favorable impact on weight and a low risk of hypoglycemia in patients with T2DM. Watch this expert-led activity to learn about GLP-1 RA options and get practical advice for integrating them into personalized care. Upon completion of this activity, participants should be better able to: Differentiate GLP-1 RAs and other glucose-lowering agents with regard to their current placement in treatment guidelines, glycemic and extra-glycemic effects, safety, ease of administration, and dosing frequency; Identify people with T2DM who would benefit from the glycemic and extra-glycemic effects of GLP-1 RAs to reduce cardiometabolic and renal risks, improve long-term health outcomes, and increase treatment adherence; and Incorporate GLP-1 RAs into personalized treatment regimens early to reduce cardiometabolic and renal risks in people with T2DM

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Vanita R. Aroda, MD - Leveraging Early GLP-1 RA Initiation to Reduce Risks and Improve Long-Term Outcomes in Patients With T2DM

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 28, 2023 58:51


Go online to PeerView.com/WEU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. People with type 2 diabetes mellitus (T2DM) deserve care that is timely and of the appropriate intensity to reduce risks and improve long-term outcomes. To that end, GLP-1 receptor agonists (RAs) must be considered in a new light. Their role has escalated in recent years, including their positioning in treatment, due to their multifaceted mechanisms of action and the collective body of evidence validating their glycemic and extra-glycemic effects. In fact, these agents have consistently demonstrated high glycemic efficacy while reducing cardiovascular and renal risks with a favorable impact on weight and a low risk of hypoglycemia in patients with T2DM. Watch this expert-led activity to learn about GLP-1 RA options and get practical advice for integrating them into personalized care. Upon completion of this activity, participants should be better able to: Differentiate GLP-1 RAs and other glucose-lowering agents with regard to their current placement in treatment guidelines, glycemic and extra-glycemic effects, safety, ease of administration, and dosing frequency; Identify people with T2DM who would benefit from the glycemic and extra-glycemic effects of GLP-1 RAs to reduce cardiometabolic and renal risks, improve long-term health outcomes, and increase treatment adherence; and Incorporate GLP-1 RAs into personalized treatment regimens early to reduce cardiometabolic and renal risks in people with T2DM

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Vanita R. Aroda, MD - Leveraging Early GLP-1 RA Initiation to Reduce Risks and Improve Long-Term Outcomes in Patients With T2DM

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 28, 2023 58:51


Go online to PeerView.com/WEU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. People with type 2 diabetes mellitus (T2DM) deserve care that is timely and of the appropriate intensity to reduce risks and improve long-term outcomes. To that end, GLP-1 receptor agonists (RAs) must be considered in a new light. Their role has escalated in recent years, including their positioning in treatment, due to their multifaceted mechanisms of action and the collective body of evidence validating their glycemic and extra-glycemic effects. In fact, these agents have consistently demonstrated high glycemic efficacy while reducing cardiovascular and renal risks with a favorable impact on weight and a low risk of hypoglycemia in patients with T2DM. Watch this expert-led activity to learn about GLP-1 RA options and get practical advice for integrating them into personalized care. Upon completion of this activity, participants should be better able to: Differentiate GLP-1 RAs and other glucose-lowering agents with regard to their current placement in treatment guidelines, glycemic and extra-glycemic effects, safety, ease of administration, and dosing frequency; Identify people with T2DM who would benefit from the glycemic and extra-glycemic effects of GLP-1 RAs to reduce cardiometabolic and renal risks, improve long-term health outcomes, and increase treatment adherence; and Incorporate GLP-1 RAs into personalized treatment regimens early to reduce cardiometabolic and renal risks in people with T2DM

PeerView Clinical Pharmacology CME/CNE/CPE Video
Vanita R. Aroda, MD - Leveraging Early GLP-1 RA Initiation to Reduce Risks and Improve Long-Term Outcomes in Patients With T2DM

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jul 28, 2023 58:55


Go online to PeerView.com/WEU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. People with type 2 diabetes mellitus (T2DM) deserve care that is timely and of the appropriate intensity to reduce risks and improve long-term outcomes. To that end, GLP-1 receptor agonists (RAs) must be considered in a new light. Their role has escalated in recent years, including their positioning in treatment, due to their multifaceted mechanisms of action and the collective body of evidence validating their glycemic and extra-glycemic effects. In fact, these agents have consistently demonstrated high glycemic efficacy while reducing cardiovascular and renal risks with a favorable impact on weight and a low risk of hypoglycemia in patients with T2DM. Watch this expert-led activity to learn about GLP-1 RA options and get practical advice for integrating them into personalized care. Upon completion of this activity, participants should be better able to: Differentiate GLP-1 RAs and other glucose-lowering agents with regard to their current placement in treatment guidelines, glycemic and extra-glycemic effects, safety, ease of administration, and dosing frequency; Identify people with T2DM who would benefit from the glycemic and extra-glycemic effects of GLP-1 RAs to reduce cardiometabolic and renal risks, improve long-term health outcomes, and increase treatment adherence; and Incorporate GLP-1 RAs into personalized treatment regimens early to reduce cardiometabolic and renal risks in people with T2DM

PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
Vanita R. Aroda, MD - Leveraging Early GLP-1 RA Initiation to Reduce Risks and Improve Long-Term Outcomes in Patients With T2DM

PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 28, 2023 58:51


Go online to PeerView.com/WEU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. People with type 2 diabetes mellitus (T2DM) deserve care that is timely and of the appropriate intensity to reduce risks and improve long-term outcomes. To that end, GLP-1 receptor agonists (RAs) must be considered in a new light. Their role has escalated in recent years, including their positioning in treatment, due to their multifaceted mechanisms of action and the collective body of evidence validating their glycemic and extra-glycemic effects. In fact, these agents have consistently demonstrated high glycemic efficacy while reducing cardiovascular and renal risks with a favorable impact on weight and a low risk of hypoglycemia in patients with T2DM. Watch this expert-led activity to learn about GLP-1 RA options and get practical advice for integrating them into personalized care. Upon completion of this activity, participants should be better able to: Differentiate GLP-1 RAs and other glucose-lowering agents with regard to their current placement in treatment guidelines, glycemic and extra-glycemic effects, safety, ease of administration, and dosing frequency; Identify people with T2DM who would benefit from the glycemic and extra-glycemic effects of GLP-1 RAs to reduce cardiometabolic and renal risks, improve long-term health outcomes, and increase treatment adherence; and Incorporate GLP-1 RAs into personalized treatment regimens early to reduce cardiometabolic and renal risks in people with T2DM

Academic Medicine Podcast
The Joys of Clinical Trials

Academic Medicine Podcast

Play Episode Listen Later Nov 28, 2022 5:07


This one, brief moment opened me up to the greatest sense of appreciation; regardless of the treatment arm, role, or results, it is the journey we embark on together, side by side with our participants, teams, and peers, that will contribute to our greater collective knowledge, advances in care, and a better future. Vanita R. Aroda, director of diabetes clinical research at Brigham and Women's Hospital and associate professor of medicine at Harvard Medical School in Boston, Massachusetts, reflects on how acting as a clinical trial investigator has changed her approach to life. The essay read in this episode was published in the Teaching and Learning Moments column in the November 2022 issue of Academic Medicine. Read the essay at academicmedicine.org.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
"Vanita R. Aroda, MD - Determining Which Patients Will Benefit From GLP-1 RAs: Applying Guidelines and Evidence to Individualize Treatment Decisions in T2DM"

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 26, 2021 19:41


Go online to PeerView.com/KMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) discusses how GLP-1 RAs can be integrated into individualized treatment plans to improve outcomes for patients with T2DM. Upon completion of this accredited CE activity, participants should be better able to: Describe the mechanisms of action of GLP-1 RAs and the rationale for the prioritization in current treatment guidelines for managing patients with T2DM, particularly those with cardiovascular or renal disease, Assess the efficacy, safety, mode of administration, benefits, and limitations for currently available GLP-1 RAs, Personalize treatment regimens for patients with T2DM using GLP-1 RAs that are consistent with individual patient goals, preferences, and priorities.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
"Vanita R. Aroda, MD - Determining Which Patients Will Benefit From GLP-1 RAs: Applying Guidelines and Evidence to Individualize Treatment Decisions in T2DM"

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 26, 2021 20:47


Go online to PeerView.com/KMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) discusses how GLP-1 RAs can be integrated into individualized treatment plans to improve outcomes for patients with T2DM. Upon completion of this accredited CE activity, participants should be better able to: Describe the mechanisms of action of GLP-1 RAs and the rationale for the prioritization in current treatment guidelines for managing patients with T2DM, particularly those with cardiovascular or renal disease, Assess the efficacy, safety, mode of administration, benefits, and limitations for currently available GLP-1 RAs, Personalize treatment regimens for patients with T2DM using GLP-1 RAs that are consistent with individual patient goals, preferences, and priorities.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
"Vanita R. Aroda, MD - Determining Which Patients Will Benefit From GLP-1 RAs: Applying Guidelines and Evidence to Individualize Treatment Decisions in T2DM"

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 26, 2021 19:41


Go online to PeerView.com/KMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) discusses how GLP-1 RAs can be integrated into individualized treatment plans to improve outcomes for patients with T2DM. Upon completion of this accredited CE activity, participants should be better able to: Describe the mechanisms of action of GLP-1 RAs and the rationale for the prioritization in current treatment guidelines for managing patients with T2DM, particularly those with cardiovascular or renal disease, Assess the efficacy, safety, mode of administration, benefits, and limitations for currently available GLP-1 RAs, Personalize treatment regimens for patients with T2DM using GLP-1 RAs that are consistent with individual patient goals, preferences, and priorities.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
"Vanita R. Aroda, MD - Determining Which Patients Will Benefit From GLP-1 RAs: Applying Guidelines and Evidence to Individualize Treatment Decisions in T2DM"

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 26, 2021 20:47


Go online to PeerView.com/KMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) discusses how GLP-1 RAs can be integrated into individualized treatment plans to improve outcomes for patients with T2DM. Upon completion of this accredited CE activity, participants should be better able to: Describe the mechanisms of action of GLP-1 RAs and the rationale for the prioritization in current treatment guidelines for managing patients with T2DM, particularly those with cardiovascular or renal disease, Assess the efficacy, safety, mode of administration, benefits, and limitations for currently available GLP-1 RAs, Personalize treatment regimens for patients with T2DM using GLP-1 RAs that are consistent with individual patient goals, preferences, and priorities.

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
"Vanita R. Aroda, MD - Determining Which Patients Will Benefit From GLP-1 RAs: Applying Guidelines and Evidence to Individualize Treatment Decisions in T2DM"

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 26, 2021 20:47


Go online to PeerView.com/KMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) discusses how GLP-1 RAs can be integrated into individualized treatment plans to improve outcomes for patients with T2DM. Upon completion of this accredited CE activity, participants should be better able to: Describe the mechanisms of action of GLP-1 RAs and the rationale for the prioritization in current treatment guidelines for managing patients with T2DM, particularly those with cardiovascular or renal disease, Assess the efficacy, safety, mode of administration, benefits, and limitations for currently available GLP-1 RAs, Personalize treatment regimens for patients with T2DM using GLP-1 RAs that are consistent with individual patient goals, preferences, and priorities.

PeerView Clinical Pharmacology CME/CNE/CPE Video
"Vanita R. Aroda, MD - Determining Which Patients Will Benefit From GLP-1 RAs: Applying Guidelines and Evidence to Individualize Treatment Decisions in T2DM"

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jul 26, 2021 20:47


Go online to PeerView.com/KMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) discusses how GLP-1 RAs can be integrated into individualized treatment plans to improve outcomes for patients with T2DM. Upon completion of this accredited CE activity, participants should be better able to: Describe the mechanisms of action of GLP-1 RAs and the rationale for the prioritization in current treatment guidelines for managing patients with T2DM, particularly those with cardiovascular or renal disease, Assess the efficacy, safety, mode of administration, benefits, and limitations for currently available GLP-1 RAs, Personalize treatment regimens for patients with T2DM using GLP-1 RAs that are consistent with individual patient goals, preferences, and priorities.

PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
"Vanita R. Aroda, MD - Determining Which Patients Will Benefit From GLP-1 RAs: Applying Guidelines and Evidence to Individualize Treatment Decisions in T2DM"

PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 26, 2021 19:41


Go online to PeerView.com/KMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) discusses how GLP-1 RAs can be integrated into individualized treatment plans to improve outcomes for patients with T2DM. Upon completion of this accredited CE activity, participants should be better able to: Describe the mechanisms of action of GLP-1 RAs and the rationale for the prioritization in current treatment guidelines for managing patients with T2DM, particularly those with cardiovascular or renal disease, Assess the efficacy, safety, mode of administration, benefits, and limitations for currently available GLP-1 RAs, Personalize treatment regimens for patients with T2DM using GLP-1 RAs that are consistent with individual patient goals, preferences, and priorities.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
"Vanita R. Aroda, MD - Determining Which Patients Will Benefit From GLP-1 RAs: Applying Guidelines and Evidence to Individualize Treatment Decisions in T2DM"

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 26, 2021 19:41


Go online to PeerView.com/KMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) discusses how GLP-1 RAs can be integrated into individualized treatment plans to improve outcomes for patients with T2DM. Upon completion of this accredited CE activity, participants should be better able to: Describe the mechanisms of action of GLP-1 RAs and the rationale for the prioritization in current treatment guidelines for managing patients with T2DM, particularly those with cardiovascular or renal disease, Assess the efficacy, safety, mode of administration, benefits, and limitations for currently available GLP-1 RAs, Personalize treatment regimens for patients with T2DM using GLP-1 RAs that are consistent with individual patient goals, preferences, and priorities.

PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
"Vanita R. Aroda, MD - Determining Which Patients Will Benefit From GLP-1 RAs: Applying Guidelines and Evidence to Individualize Treatment Decisions in T2DM"

PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 26, 2021 20:47


Go online to PeerView.com/KMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) discusses how GLP-1 RAs can be integrated into individualized treatment plans to improve outcomes for patients with T2DM. Upon completion of this accredited CE activity, participants should be better able to: Describe the mechanisms of action of GLP-1 RAs and the rationale for the prioritization in current treatment guidelines for managing patients with T2DM, particularly those with cardiovascular or renal disease, Assess the efficacy, safety, mode of administration, benefits, and limitations for currently available GLP-1 RAs, Personalize treatment regimens for patients with T2DM using GLP-1 RAs that are consistent with individual patient goals, preferences, and priorities.

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
"Vanita R. Aroda, MD - Determining Which Patients Will Benefit From GLP-1 RAs: Applying Guidelines and Evidence to Individualize Treatment Decisions in T2DM"

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 26, 2021 19:41


Go online to PeerView.com/KMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) discusses how GLP-1 RAs can be integrated into individualized treatment plans to improve outcomes for patients with T2DM. Upon completion of this accredited CE activity, participants should be better able to: Describe the mechanisms of action of GLP-1 RAs and the rationale for the prioritization in current treatment guidelines for managing patients with T2DM, particularly those with cardiovascular or renal disease, Assess the efficacy, safety, mode of administration, benefits, and limitations for currently available GLP-1 RAs, Personalize treatment regimens for patients with T2DM using GLP-1 RAs that are consistent with individual patient goals, preferences, and priorities.

PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
Vanita R. Aroda, MD - Test Your Knowledge: Current Guidance on GLP-1 Receptor Agonists to Individualize Treatment for T2DM

PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 24, 2020 33:13


Go online to PeerView.com/YEQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) reviews glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and describes strategies to individualize treatment for patients with T2DM using GLP-1 RAs. Upon completion of this activity, participants should be better able to: Summarize current guidelines and FDA-approved indications regarding the use of GLP-1 RAs in patients with T2DM, Differentiate current GLP-1 RAs from other classes of glucose-lowering agents and from one another when used to treat appropriate patients with T2DM, Assess the benefits and risks of GLP-1 RAs based on results from recent cardiovascular outcomes trials in terms of cardiorenal prevention.

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Vanita R. Aroda, MD - Test Your Knowledge: Current Guidance on GLP-1 Receptor Agonists to Individualize Treatment for T2DM

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 24, 2020 33:13


Go online to PeerView.com/YEQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) reviews glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and describes strategies to individualize treatment for patients with T2DM using GLP-1 RAs. Upon completion of this activity, participants should be better able to: Summarize current guidelines and FDA-approved indications regarding the use of GLP-1 RAs in patients with T2DM, Differentiate current GLP-1 RAs from other classes of glucose-lowering agents and from one another when used to treat appropriate patients with T2DM, Assess the benefits and risks of GLP-1 RAs based on results from recent cardiovascular outcomes trials in terms of cardiorenal prevention.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Vanita R. Aroda, MD - Test Your Knowledge: Current Guidance on GLP-1 Receptor Agonists to Individualize Treatment for T2DM

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 24, 2020 33:13


Go online to PeerView.com/YEQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) reviews glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and describes strategies to individualize treatment for patients with T2DM using GLP-1 RAs. Upon completion of this activity, participants should be better able to: Summarize current guidelines and FDA-approved indications regarding the use of GLP-1 RAs in patients with T2DM, Differentiate current GLP-1 RAs from other classes of glucose-lowering agents and from one another when used to treat appropriate patients with T2DM, Assess the benefits and risks of GLP-1 RAs based on results from recent cardiovascular outcomes trials in terms of cardiorenal prevention.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Vanita R. Aroda, MD - Test Your Knowledge: Current Guidance on GLP-1 Receptor Agonists to Individualize Treatment for T2DM

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 24, 2020 33:13


Go online to PeerView.com/YEQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) reviews glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and describes strategies to individualize treatment for patients with T2DM using GLP-1 RAs. Upon completion of this activity, participants should be better able to: Summarize current guidelines and FDA-approved indications regarding the use of GLP-1 RAs in patients with T2DM, Differentiate current GLP-1 RAs from other classes of glucose-lowering agents and from one another when used to treat appropriate patients with T2DM, Assess the benefits and risks of GLP-1 RAs based on results from recent cardiovascular outcomes trials in terms of cardiorenal prevention.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Vanita R. Aroda, MD - Test Your Knowledge: Current Guidance on GLP-1 Receptor Agonists to Individualize Treatment for T2DM

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 24, 2020 33:13


Go online to PeerView.com/YEQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) reviews glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and describes strategies to individualize treatment for patients with T2DM using GLP-1 RAs. Upon completion of this activity, participants should be better able to: Summarize current guidelines and FDA-approved indications regarding the use of GLP-1 RAs in patients with T2DM, Differentiate current GLP-1 RAs from other classes of glucose-lowering agents and from one another when used to treat appropriate patients with T2DM, Assess the benefits and risks of GLP-1 RAs based on results from recent cardiovascular outcomes trials in terms of cardiorenal prevention.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Vanita R. Aroda, MD - Test Your Knowledge: Current Guidance on GLP-1 Receptor Agonists to Individualize Treatment for T2DM

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 24, 2020 33:13


Go online to PeerView.com/YEQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) reviews glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and describes strategies to individualize treatment for patients with T2DM using GLP-1 RAs. Upon completion of this activity, participants should be better able to: Summarize current guidelines and FDA-approved indications regarding the use of GLP-1 RAs in patients with T2DM, Differentiate current GLP-1 RAs from other classes of glucose-lowering agents and from one another when used to treat appropriate patients with T2DM, Assess the benefits and risks of GLP-1 RAs based on results from recent cardiovascular outcomes trials in terms of cardiorenal prevention.

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Vanita R. Aroda, MD - Putting Basal Insulin Therapy to Work for Patients With Type 2 Diabetes Mellitus

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later Sep 27, 2019 53:02


Go online to PeerView.com/HMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist discusses the use of basal insulin therapy to manage patients with type 2 diabetes mellitus (T2DM), focusing on identifying patients who should receive insulin, overcoming common barriers to insulin use, navigating the currently approved basal insulins, and providing evidence-based guidance for insulin titration. Upon completion of this activity, participants should be better able to: Identify clinically relevant differences between currently available basal insulins, Assess the candidacy of patients with T2DM for treatment with basal insulin therapy according to current treatment guidelines, Educate patients with T2DM on how to initiate and adjust basal insulin doses to minimize the risk of hypoglycemia.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Vanita R. Aroda, MD - Putting Basal Insulin Therapy to Work for Patients With Type 2 Diabetes Mellitus

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Sep 27, 2019 52:58


Go online to PeerView.com/HMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist discusses the use of basal insulin therapy to manage patients with type 2 diabetes mellitus (T2DM), focusing on identifying patients who should receive insulin, overcoming common barriers to insulin use, navigating the currently approved basal insulins, and providing evidence-based guidance for insulin titration. Upon completion of this activity, participants should be better able to: Identify clinically relevant differences between currently available basal insulins, Assess the candidacy of patients with T2DM for treatment with basal insulin therapy according to current treatment guidelines, Educate patients with T2DM on how to initiate and adjust basal insulin doses to minimize the risk of hypoglycemia.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Vanita R. Aroda, MD - Putting Basal Insulin Therapy to Work for Patients With Type 2 Diabetes Mellitus

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Sep 27, 2019 52:58


Go online to PeerView.com/HMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist discusses the use of basal insulin therapy to manage patients with type 2 diabetes mellitus (T2DM), focusing on identifying patients who should receive insulin, overcoming common barriers to insulin use, navigating the currently approved basal insulins, and providing evidence-based guidance for insulin titration. Upon completion of this activity, participants should be better able to: Identify clinically relevant differences between currently available basal insulins, Assess the candidacy of patients with T2DM for treatment with basal insulin therapy according to current treatment guidelines, Educate patients with T2DM on how to initiate and adjust basal insulin doses to minimize the risk of hypoglycemia.

PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
Vanita R. Aroda, MD - Putting Basal Insulin Therapy to Work for Patients With Type 2 Diabetes Mellitus

PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast

Play Episode Listen Later Sep 27, 2019 53:02


Go online to PeerView.com/HMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist discusses the use of basal insulin therapy to manage patients with type 2 diabetes mellitus (T2DM), focusing on identifying patients who should receive insulin, overcoming common barriers to insulin use, navigating the currently approved basal insulins, and providing evidence-based guidance for insulin titration. Upon completion of this activity, participants should be better able to: Identify clinically relevant differences between currently available basal insulins, Assess the candidacy of patients with T2DM for treatment with basal insulin therapy according to current treatment guidelines, Educate patients with T2DM on how to initiate and adjust basal insulin doses to minimize the risk of hypoglycemia.

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Vanita R. Aroda, MD - Putting Basal Insulin Therapy to Work for Patients With Type 2 Diabetes Mellitus

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Sep 27, 2019 53:02


Go online to PeerView.com/HMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist discusses the use of basal insulin therapy to manage patients with type 2 diabetes mellitus (T2DM), focusing on identifying patients who should receive insulin, overcoming common barriers to insulin use, navigating the currently approved basal insulins, and providing evidence-based guidance for insulin titration. Upon completion of this activity, participants should be better able to: Identify clinically relevant differences between currently available basal insulins, Assess the candidacy of patients with T2DM for treatment with basal insulin therapy according to current treatment guidelines, Educate patients with T2DM on how to initiate and adjust basal insulin doses to minimize the risk of hypoglycemia.

PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
Vanita R. Aroda, MD - Putting Basal Insulin Therapy to Work for Patients With Type 2 Diabetes Mellitus

PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast

Play Episode Listen Later Sep 27, 2019 52:58


Go online to PeerView.com/HMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist discusses the use of basal insulin therapy to manage patients with type 2 diabetes mellitus (T2DM), focusing on identifying patients who should receive insulin, overcoming common barriers to insulin use, navigating the currently approved basal insulins, and providing evidence-based guidance for insulin titration. Upon completion of this activity, participants should be better able to: Identify clinically relevant differences between currently available basal insulins, Assess the candidacy of patients with T2DM for treatment with basal insulin therapy according to current treatment guidelines, Educate patients with T2DM on how to initiate and adjust basal insulin doses to minimize the risk of hypoglycemia.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Vanita R. Aroda, MD - Putting Basal Insulin Therapy to Work for Patients With Type 2 Diabetes Mellitus

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Sep 27, 2019 53:02


Go online to PeerView.com/HMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist discusses the use of basal insulin therapy to manage patients with type 2 diabetes mellitus (T2DM), focusing on identifying patients who should receive insulin, overcoming common barriers to insulin use, navigating the currently approved basal insulins, and providing evidence-based guidance for insulin titration. Upon completion of this activity, participants should be better able to: Identify clinically relevant differences between currently available basal insulins, Assess the candidacy of patients with T2DM for treatment with basal insulin therapy according to current treatment guidelines, Educate patients with T2DM on how to initiate and adjust basal insulin doses to minimize the risk of hypoglycemia.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Vanita R. Aroda, MD - Putting Basal Insulin Therapy to Work for Patients With Type 2 Diabetes Mellitus

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Sep 27, 2019 53:02


Go online to PeerView.com/HMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist discusses the use of basal insulin therapy to manage patients with type 2 diabetes mellitus (T2DM), focusing on identifying patients who should receive insulin, overcoming common barriers to insulin use, navigating the currently approved basal insulins, and providing evidence-based guidance for insulin titration. Upon completion of this activity, participants should be better able to: Identify clinically relevant differences between currently available basal insulins, Assess the candidacy of patients with T2DM for treatment with basal insulin therapy according to current treatment guidelines, Educate patients with T2DM on how to initiate and adjust basal insulin doses to minimize the risk of hypoglycemia.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Vanita R. Aroda, MD - Putting Basal Insulin Therapy to Work for Patients With Type 2 Diabetes Mellitus

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Sep 27, 2019 52:58


Go online to PeerView.com/HMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist discusses the use of basal insulin therapy to manage patients with type 2 diabetes mellitus (T2DM), focusing on identifying patients who should receive insulin, overcoming common barriers to insulin use, navigating the currently approved basal insulins, and providing evidence-based guidance for insulin titration. Upon completion of this activity, participants should be better able to: Identify clinically relevant differences between currently available basal insulins, Assess the candidacy of patients with T2DM for treatment with basal insulin therapy according to current treatment guidelines, Educate patients with T2DM on how to initiate and adjust basal insulin doses to minimize the risk of hypoglycemia.

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Vanita R. Aroda, MD - Putting Basal Insulin Therapy to Work for Patients With Type 2 Diabetes Mellitus

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later Sep 27, 2019 52:58


Go online to PeerView.com/HMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist discusses the use of basal insulin therapy to manage patients with type 2 diabetes mellitus (T2DM), focusing on identifying patients who should receive insulin, overcoming common barriers to insulin use, navigating the currently approved basal insulins, and providing evidence-based guidance for insulin titration. Upon completion of this activity, participants should be better able to: Identify clinically relevant differences between currently available basal insulins, Assess the candidacy of patients with T2DM for treatment with basal insulin therapy according to current treatment guidelines, Educate patients with T2DM on how to initiate and adjust basal insulin doses to minimize the risk of hypoglycemia.